Development of Oncolytic Adenovirus Formulation with a Stealth Effect – Expansion from Local to Systemic Administration
December 22(Fri), 2017
Toshiyoshi Fujiwara, Professor at the Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Hiroshi Tazawa, Associate Professor, and Shinji Kuroda, Assistant Professor at the Center for Innovative Clinical Medicine, Okayama University Hospital and their research group successfully developed an oncolytic adenovirus formulation with a stealth effect that can be used for systemic administration by combining the oncolytic adenovirus with nanotechnology. Oncolytic adenovirus had been used only for local administration until now. This research success was published in the electronic version of the British science magazine “Scientific Reports” (Nature Publishing Group) on October 26, 2017.
The effectiveness of the local administration of oncolytic adenovirus has been verified in clinical trials in Japan. Further clinical development of an oncolytic adenovirus formulation that can be used for systemic administration will be helpful for the treatment of progressive cancers or cancers in areas that are hard to treat locally. The new formulation is expected to lead to further applications.
Authors: Katsuyuki Aoyama, Shinji Kuroda, Toshiaki Morihiro, Nobuhiko Kanaya, Tetsushi Kubota, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko ishizaki, Shunsuke Kagawa, Hiroshi Tazawa & Toshiyoshi Fujiwara
Journal: Scientific Reports
Title: Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.
Year of Publication: 2017
Okayama University Silicon Valley Office (OUSVO)
Contact: Mototaka Senda, Ph.D.
- Oncolytic Adenovirus Formulation, progressive cancers, cancers